NCT06267274
A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes
Phase: Phase 1
Role: Lead Sponsor
Start: Apr 1, 2024
Completion: May 1, 2025